

2023 Iran Tumor Markers Testing Market-High-Growth Opportunities for Cancer Diagnostic Tests and Analyzers-2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Segment Forecasts for over 40 Individual Cancer Markers, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers

https://marketpublishers.com/r/2E2EB3C65C9DEN.html

Date: March 2023 Pages: 0 Price: US\$ 2,000.00 (Single User License) ID: 2E2EB3C65C9DEN

# **Abstracts**

This new report from LeadingMarketResearch.com provides a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years.

The report is available by section, and can be customized to specific information needs and budget.

The report examines emerging trends in the cancer diagnostics market; reviews current and emerging tests; analyzes potential applications of innovative technologies; forecasts volume and sales for major cancer diagnostics tests; profiles leading market players and potential entrants; and suggests alternative market expansion strategies for suppliers.

# Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the cancer diagnostics market is promising to be an exciting,



dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion.

Business Opportunities and Strategic Recommendations

Specific new product development opportunities with potentially significant market appeal during the next five years.

Design criteria for new products.

Alternative market penetration strategies.

Potential market entry barriers and risks.

Cancer Diagnostic Tests Analyzed in the Report--over 200 current and emerging assays, including Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines and Immunohistochemical Stains, such as:

ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Instrumentation Review

Analysis of major immunoassay analyzers used for cancer diagnostic testing, including their operating characteristics, features and selling prices.

**Technology Review** 

Assessment of monoclonal antibodies, immunoassays, DNA probes,



biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing.

Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.

Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

**Competitive Assessments** 

Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.



# Contents

# I. INTRODUCTION

# **II. MARKET OVERVIEW**

# **III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES**

# **IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS**

**V. ALTERNATIVE MARKET PENETRATION STRATEGIES** 

# VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

#### **VII. MAJOR CURRENT AND EMERGING CANCER DIAGNOSTIC TESTS**

- 1. Introduction
- 2. Cancer Diagnostic Classification
- 3. ACTH
- 4. Alpha-Fetoprotein (AFP)
- 5. Beta-2 Microglobulin
- 6. CA 15-3/27.29
- 7. CA 19-9
- 8. CA-125
- 9. Calcitonin
- 10. Carcinoembrionic Antigen (CEA)
- 11. Estrogen and Progesterone Receptors
- 12. Ferritin
- 13. Gastrin
- 14. Human Chorionic Gonadotropin (HCG)
- 15. Insulin
- 16. NSE
- 17. Occult Blood
- 18. PAP Smear/HPV
- 19. Prostatic Acid Phosphatase (PAP)
- 20. Prostate-Specific Antigen (PSA)
- 21. Squamous Cell Carcinoma Antigen (SCC)
- 22. T and B Lymphocytes
- 23. TdT



24. Thyroglobulin 25. Tissue Polypeptide Antigen (TPA) 26. Biochemical Cancer Diagnostics 27. Oncogenes Abl/abl-bcr AIB1 BCL-2 BRCA1 **CD44** C-fos C-myb C-myc **CYP-17** Erb-B HPC1 N-myc P40 P51 P53 PIK3CA PTI-1 Ras Reg Sis Src and others 28. Polypeptide Growth Factors **Basic Fibroblast Growth Factor Beta-TGF** Cachectin (TNT) Calmodulin **ECFR** Nerve Growth Factor (NGF) Epidermal Growth Factor (EGF) **Ornithine Decarboxylase** Transferrin Transforming Growth Factor-Alpha 29. Ectopic Hormones 30. Colony Stimulating Factors

31. Lymphokines



Alpha-Interferon **B Cell Growth Factors** B Cell Growth Factor (BCGF) Gamma-Interferon Interleukin-1 (IL-1) Macrophage Activating Factor 32. Immunohistochemical Stains 33. Emerging Cancer Diagnostics N-Acetylglucosamine Actin Alpha-Actin Antineuronal Antibodies 7B2 B72.3 Bax BCD-F9 BLCA-4 Blood Group Antigens A,B,H CA CA 72-4/TAG-72 CA CA-242 CA-549 CAM CAR-3 Cathepsin-D Chromogranin A and B Cluster 1 Antigen Cluster-5/5A Antigen CTA **CU18 DR-70** DU-PAN-2 **Endometrial Bleeding Associated Factor** Endostatin **Epithelial Membrane Antigen** Feulgen Hydrolysis Fibronectin FSH



(1->3)-L-fucosyltransferase Gastrin-Releasing Peptide (GRP) GDCFP-15 Glucagon Glycoamines H23 Her-2 Human Carcinoma Antigen HPA HSP27 Intermediate Filaments Cytokeratins/CK18/Cyfra 21-1 Desmin **Gliofibrillary Acid Protein** Neurofilaments Vimentin KA **Kinases KP16D3** LAI Leukocyte Common Antigen Lewis Antigens Lysophosphatidic Acid (LPA) Ma 695/Ma MABDF3 MAG ME1 Minactivin MN/CA9 MSA Mucin Cancer Antigen (MCA) Multiple Tumor Suppressor Myosin **NEA-130** NMP22 OA-519 **Opiod Peptides** P-glycoprotein Pancreatic Oncofetal Antigen (POA)



**Placental Lactogen PR92** Proliferative Index, Ki-67 Px **RB** Inactivation/Deletion Ret SCCL Selectin Sialic Acid Sialyl SSEA-1/SLX **SN10** Somatostatin TA-90 TABA Tachykinin TAG TPS Troponin Tubulin VCAM VEGF Villen and others

# **VIII. INSTRUMENTATION REVIEW AND MARKET NEEDS**

# **IX. CURRENT AND EMERGING TECHNOLOGIES**

- 1. Monoclonal and Polyclonal Antibodies
- 2. Immunoassays
- 3. Molecular Diagnostics
- 4. Chromosome Analysis
  - a. Chronic Myelogenous Leukemia (CML)
- b. Acute Myeloid Leukemia (AML)
- c. Acute Lymphoblastic Leukemia (ALL)
- d. Malignant Lymphomas Lymphoid Malignancies
- e. Chronic Lymphocytic Leukemia (CLL)
- f. Solid Cancers
- g. Chromosomal Translocation and Oncogenes
- 5. Artificial Intelligence

2023 Iran Tumor Markers Testing Market-High-Growth Opportunities for Cancer Diagnostic Tests and Analyzers-202...



- 6. Flow Cytometry
- 7. Two Dimensional Gel Electrophoresis (2-DGE)
- 8. Biosensors
- 9. Competing/Complementing Technologies

# X. MARKET SIZE, TEST VOLUME AND SALES FORECASTS

# **XI. COMPETITIVE PROFILES**

The report provides strategic assessments of over 30 leading cancer diagnostics market players and start-up companies with innovative technologies and products, including: Abbott Affymetrix Beckman Coulter/Danaher/Cepheid **Becton Dickinson** bioMerieux **Bio-Rad** DiaSorin **Eiken Chemical** Elitech Group Enzo Biochem Fuifilm Wako Fujirebio Grifols Hologic Leica Biosystems PerkinElmer Qiagen QuidelOrtho Roche **Siemens Healthineers** Takara Bio

Thermo Fisher and others.



# I would like to order

- Product name: 2023 Iran Tumor Markers Testing Market-High-Growth Opportunities for Cancer Diagnostic Tests and Analyzers-2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Segment Forecasts for over 40 Individual Cancer Markers, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers
  - Product link: https://marketpublishers.com/r/2E2EB3C65C9DEN.html

Price: US\$ 2,000.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

# Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/2E2EB3C65C9DEN.html</u>

# To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

\*\*All fields are required

Custumer signature \_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>



To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970